Talphera Dirección

Dirección controles de criterios 3/4

Talphera's El consejero delegado es Vince Angotti , nombrado en Mar 2017, tiene un mandato de 7.08 años. la remuneración anual total es $1.30M , compuesta por 49.1% salario y 50.9% primas, incluidas acciones y opciones de la empresa. posee directamente 0.55% de las acciones de la empresa, por valor de €88.52K . La antigüedad media del equipo directivo y del consejo de administración es de 11.8 años y 7.1 años respectivamente.

Información clave

Vince Angotti

Chief Executive Officer (CEO)

US$1.3m

Compensación total

Porcentaje del salario del CEO	49.1%
Permanencia del CEO	7.1yrs
Participación del CEO	0.5%
Permanencia media de la dirección	11.8yrs
Promedio de permanencia en la Junta Directiva	7.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Vince Angotti en comparación con los beneficios de Talphera?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$10m
Sep 30 2023	n/a	n/a	-US$11m
Jun 30 2023	n/a	n/a	-US$14m
Mar 31 2023	n/a	n/a	US$42m
Dec 31 2022	US$1m	US$637k	US$54m
Sep 30 2022	n/a	n/a	US$69m
Jun 30 2022	n/a	n/a	US$65m
Mar 31 2022	n/a	n/a	-US$31m
Dec 31 2021	US$2m	US$637k	-US$17m
Sep 30 2021	n/a	n/a	-US$36m
Jun 30 2021	n/a	n/a	-US$37m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$2m	US$637k	-US$40m
Sep 30 2020	n/a	n/a	-US$46m
Jun 30 2020	n/a	n/a	-US$50m
Mar 31 2020	n/a	n/a	-US$55m
Dec 31 2019	US$2m	US$618k	-US$53m
Sep 30 2019	n/a	n/a	-US$51m
Jun 30 2019	n/a	n/a	-US$51m
Mar 31 2019	n/a	n/a	-US$49m
Dec 31 2018	US$2m	US$600k	-US$47m
Sep 30 2018	n/a	n/a	-US$44m
Jun 30 2018	n/a	n/a	-US$45m
Mar 31 2018	n/a	n/a	-US$48m
Dec 31 2017	US$2m	US$493k	-US$52m

Compensación vs. Mercado: Vince($USD1.30M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD414.42K).

Compensación vs. Ingresos: La compensación de Vince ha sido consistente con los resultados de la empresa en el último año.

CEO

Vince Angotti (55 yo)

7.1yrs

Permanencia

US$1,297,016

Compensación

Mr. Vincent J. Angotti, also known as Vince, has been the Chief Executive Officer of Talphera, Inc. (formerly known as AcelRx Pharmaceuticals, Inc.) since March 6, 2017. Mr. Angotti served as the Chief Exe...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Vincent Angotti	CEO & Director	7.1yrs	US$1.30m	0.55% $ 99.2k
Pamela Palmer	Co-Founder & Chief Medical Officer	18.8yrs	US$822.40k	0.21% $ 37.5k
Raffi Asadorian	Chief Financial Officer	6.7yrs	US$755.14k	0.082% $ 14.8k
Anil Dasu	Chief Engineering Officer	16.6yrs	US$686.35k	0.070% $ 12.7k

11.8yrs

Permanencia media

57.5yo

Promedio de edad

Equipo directivo experimentado: R5XAEl equipo directivo de la empresa es veterano y experimentado (11.7 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Vincent Angotti	CEO & Director	7.1yrs	US$1.30m	0.55% $ 99.2k
Mark Allen Wan	Independent Director	17.7yrs	US$76.50k	0.011% $ 2.0k
Stephen Hoffman	Independent Director	14.2yrs	US$56.50k	0.011% $ 2.0k
William Schmidt	Member of Medical Advisory Board	no data	sin datos	sin datos
Adrian Adams	Independent Chairman	11.2yrs	US$111.50k	0.066% $ 12.0k
Marina Bozilenko	Independent Director	3.1yrs	US$66.50k	0.010% $ 1.9k
Jill Broadfoot	Independent Director	2.4yrs	US$66.50k	0.0060% $ 1.1k
Eugene Viscusi	Member of Medical Advisory Board	no data	sin datos	sin datos
Jonathan Schaffer	Member of Medical Advisory Board	no data	sin datos	sin datos
Mary Southam	Member of Medical Advisory Board	no data	sin datos	sin datos
Katsuto Shinohara	Member of Medical Advisory Board	no data	sin datos	sin datos
Abhinav Jain	Director	less than a year	sin datos	sin datos

7.1yrs

Permanencia media

59.5yo

Promedio de edad

Junta con experiencia: La junta directiva de R5XA se considera experimentada (7 años de antigüedad promedio).

Talphera Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Talphera, Inc. Appoints Abhinav Jain to Serve as a Class II Director

AcelRx Pharmaceuticals, Inc., Annual General Meeting, Oct 10, 2023

AcelRx Pharmaceuticals, Inc. Announces Resignation of Mark G. Edwards as Board of Director

Recent updates

Talphera, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Talphera, Inc. Appoints Abhinav Jain to Serve as a Class II Director

Talphera, Inc.(NasdaqGM:TLPH) dropped from NASDAQ Composite Index

Talphera Expects to Initiate the Registrational Study of Niyad

New major risk - Financial position

AcelRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

AcelRx Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

AcelRx Pharmaceuticals, Inc. Receives IDE Approval for Niyad and Advances to A Single Registration Study

AcelRx Pharmaceuticals, Inc., Annual General Meeting, Oct 10, 2023

New minor risk - Profitability

AcelRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Shareholder dilution

Acelrx Pharmaceuticals Inc. Regains Compliance with Nasdaq Minimum Bid Price Rule

First quarter 2023 earnings released: EPS: US$0.006 (vs US$1.19 loss in 1Q 2022)

Full year 2022 earnings released: EPS: US$5.73 (vs US$5.86 loss in FY 2021)

Third quarter 2022 earnings released: US$0.92 loss per share (vs US$1.41 loss in 3Q 2021)

AcelRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022

AcelRx Pharmaceuticals Announces Reverse Stock Split to Regain Compliance

Second quarter 2022 earnings released: EPS: US$0.48 (vs US$0.083 loss in 2Q 2021)

AcelRx Pharmaceuticals, Inc. announced that it has received $0.3 million in funding from Lincoln Park Capital, LLC

Nasdaq Grants Additional time to AcelRx Pharmaceuticals to Regain Compliance

AcelRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

AcelRx Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

AcelRx Pharmaceuticals, Inc. Provides Update on Reduced FDA REMS Requirements Related to DSUVIA

First quarter 2022 earnings released: US$0.06 loss per share (vs US$0.079 loss in 1Q 2021)

Acelrx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (Sst) Compared to Standard Intravenous Opioids During Plastic Surgery Procedures Performed Under General Anesthesia

AcelRx Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

AcelRx Pharmaceuticals, Inc. Announces Summary of Results from Podium Presentation on DSUVIA, at the Aesthetic Meeting 2022

AcelRx Pharmaceuticals, Inc. Announces Publication of A Study Evaluating the Use of A Sufentanil Sublingual Tablet 30 Mcg for Management of Pain of Radiofrequency Microneedling of the Face or Abdomen

AcelRx Pharmaceuticals, Inc. Announces the Publication of Comparative Data Between Two Different Dialysis Circuit Anticoagulants in Pediatric Patients Undergoing Continuous Renal Replacement Therapy

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

AcelRx Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

AcelRx Pharmaceuticals, Inc. Announces Resignation of Mark G. Edwards as Board of Director

AcelRx Pharmaceuticals, Inc. Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet During Awake Plastic Surgery Procedures

AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX) completed the acquisition of Lowell Therapeutics, Inc.

AcelRx Pharmaceuticals, Inc. Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery

Third quarter 2021 earnings released: US$0.07 loss per share (vs US$0.10 loss in 3Q 2020)

Forecast to breakeven in 2022

Second quarter 2021 earnings released: US$0.083 loss per share (vs US$0.082 loss in 2Q 2020)

AcelRx Pharmaceuticals, Inc.(NasdaqGM:ACRX) dropped from Russell 3000E Value Index

Rosen Law Firm Reminds Purchasers of the Securities of Acelrx Pharmaceuticals, Inc. Between March 17, 2020 and February 12, 2021

Pomerantz Law Firm Announces the Filing of A Class Action Against AcelRX Pharmaceuticals, Inc. and Certain Officers

AcelRx Pharmaceuticals, Inc. Announces Important Findings from A Podium Presentation on DSUVIA

AcelRx Pharmaceuticals, Inc. Announces an Investigator-Initiated Study of DSUVIA in the Emergency Department for Patients with Sickle Cell Disease

Forecast breakeven pushed back to 2023

First quarter 2021 earnings released: US$0.079 loss per share (vs US$0.20 loss in 1Q 2020)

AcelRx Announces an Investigator-Initiated Study of DSUVIA® for Use in Same-Day Total Joint Replacement

Full year 2020 earnings released: US$0.47 loss per share (vs US$0.67 loss in FY 2019)

AcelRx Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 15, 2021

AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Plastic Surgery Procedures

New 90-day high: €2.22

AcelRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $27.5 million.

AcelRx Pharmaceuticals, Inc. Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery Enhanced Recovery Regimen

New 90-day high: €1.65

New 90-day low: €0.94

New 90-day low: €1.07

AcelRx Pharmaceuticals, Inc. Announces Publication of Clinical Data on Decreased Postoperative Opioid Requirements and Enhanced Postanesthesia Recovery Following Perioperative Use of DSUVIA®

AcelRx Pharmaceuticals Inc. Announces Partnership with the National Rural Health Association

AcelRx Pharmaceuticals Announces Commentary in Practical Pain Management on Previously Published Clinical Data on Preoperative Administration of DSUVIA®

Revenue misses expectations

Third quarter 2020 earnings released: US$0.10 loss per share

AcelRx Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day high: €1.59

AcelRx Pharmaceuticals, Inc. Secures United States Army Contract for DSUVIA

New 90-day low - €0.90

First half earnings released

AcelRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $10 million.

AcelRx Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Análisis de compensación del CEO

CEO

Permanencia